warning: Creating default object from empty value in /home/cpnhelp/www/www/modules/taxonomy/taxonomy.pages.inc on line 33.
Anti-bacterial agent used in Cpn to kill the cryptic intracellular form.

Preview of Wheldon/Stratton Research

Preliminary summary of work-in-progress: METRONIDAZOLE: A KEY COMPONENT OF A REGIMEN FOR THE TREATMENT OF PERSISTENT CHLAMYDOPHILA (CHLAMYDIA) PNEUMONIAE INFECTION. David B. Wheldon(a) and Charles W. Stratton(b) (a) Consultant Medical Microbiologist, Department of Medical Microbiology, Bedford Hospital, Kempston Road, Bedford, UK MK42 9DJ. Corresponding Author. tel 01234355122 ext 5282; email david.wheldon@bedhos.anglox.nhs.uk (b) Associate Professor of Pathology, The Vanderbilt Clinic 4524-TVC, Vanderbilt University Medical Center, 21st & Edgehill St. Nashville, TN 37232-5310 USA email charles.stratton@vanderbilt.edu Diagnosis and treatment of chronic persistent infections with Chlamydia pneumoniae are both problematic. This is important because evidence is accumulating that this organism has input into serious multisystem diseases. The authors examine the dynamic of chronic persistent infections with Chlamydia pneumoniae and suggest that a host tryptophan starvation strategy together with the administration of protein-synthesis inhibitors may drive the organism into a sluggish metabolic state which relies on anaerobic pathways. They draw parallels with other intracellular pathogens (e.g. Mycobacterium tuberculosis) which are known to do this. Organisms in this state would be expected to be killed by metronidazole. The authors anticipate that, as chlamydiae possess endotoxins, cidal treatment should bring about symptoms of endotoxaemia. Seven patients with symptoms suggestive of chronic persistent Chlamydia pneumoniae infection (five of them with positive IF serology) were treated with doxycycline and a macrolide. When metronidazole was added to the regimen the patients developed chills, sweats and other symptoms suggestive of mild endotoxic reactions. The authors make the point that these reactions continued after the metronidazole had been discontinued, suggesting a) treatment may purge immune system cells (known to be a target of Chlamydia pneumoniae) of the organism, and b) may have opened up the constitution of the organism to the host immune system. The study is flawed by the fact that it is retrospective, and that endotoxin assay (which is not a routine examination) was not undertaken.

Earlier Version of the Vanderbilt Protocol: Stratton, et al.

Please note: this is an earlier version of the Vanderbilt protocol developed by Dr. Stratton and his colleagues. It is here because it contains useful treatment info for reference. Please see Dr. Stratton's current protocol in the Cpn Handbbook. <


Vanderbilt University has some of the world's experts on Cpn, and has been testing antibiotic treatment especially with MSi. The Mitchell/Stratton, et al patent has highly detailed information about the testing and treatment they have developed, and can be found at this link<.

Syndicate content